GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.20% | 8.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.41% | -7.73% | |||
| Operating Income | -4.41% | 7.73% | |||
| Income Before Tax | -10.67% | 8.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.67% | 8.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.67% | 8.06% | |||
| EBIT | -4.41% | 7.73% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -9.54% | 29.56% | |||
| Normalized Basic EPS | -9.44% | 29.53% | |||
| EPS Diluted | -9.54% | 29.56% | |||
| Normalized Diluted EPS | -9.44% | 29.53% | |||
| Average Basic Shares Outstanding | 1.04% | 30.51% | |||
| Average Diluted Shares Outstanding | 1.04% | 30.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||